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Evaluation of a Rapid Membrane Enzyme 
Immunoassay for the Simultaneous Detection of 
Glutamate Dehydrogenase and Toxin for the Diagnosis 
of Clostridium difficile Infection
Heejung Kim, M.D., Wan Hee Kim, B.S., Myungsook Kim, M.T., Seok Hoon Jeong, M.D., and Kyungwon Lee, M.D.
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea
We evaluated the new C. DIFF QUIK CHEK COMPLETE (CD COMPLETE; TechLab, USA), 
which is a rapid membrane enzyme immunoassay that uses a combination of glutamate 
dehydrogenase (GDH) antigen and toxin A and B detection. A total of 608 consecutive 
loose stool specimens collected from the patients with suspected Clostridium difficile infec-
tion (CDI) from August to December 2012 were subjected to the CD COMPLETE and VIDAS 
Clostridium difficile A & B (VIDAS CDAB; bioMérieux, France). Their performances were 
compared with a toxigenic culture as a reference. Stool specimens that were culture-nega-
tive and CD COMPLETE- or VIDAS CDAB-positive were analyzed by using an enrichment 
procedure. In comparison to the toxigenic cultures, sensitivity, specificity, positive predictive 
values (PPV), and negative predictive values (NPV) were 63.6%, 98.0%, 76.1%, and 
96.4%, respectively, for the CD COMPLETE-toxin and 75.5%, 97.4%, 72.5%, and 97.8%, 
respectively, for the VIDAS CDAB. In comparison to the enriched C. difficile cultures, the 
sensitivity, specificity, PPV, and NPV for the CD COMPLETE-GDH were 91.0%, 92.4%, 
70.5%, and 98.1%, respectively. The CD COMPLETE is a reliable method for the diagnosis 
of CDI and provides greater sensitivity than toxin enzyme immunoassay alone. Furthermore, 
the CD COMPLETE-GDH has advantages over direct culture in detecting C. difficile.
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Clostridium difficile is a major causative agent of pseudomem-
branous colitis, antibiotic-associated diarrhea, and colitis. Toxins 
A (enterotoxin; TcdA) and B (cytotoxin; TcdB) are well-known 
primary virulence factors of C. difficile. C. difficile infections (CDI) 
have recently increased in both number and severity [1]. Thus, 
rapid and accurate diagnosis of CDI is of great importance, and 
laboratories are challenged to provide cost-effective, rapid, and 
accurate results [2-4]. The diagnosis of CDI should be based on 
a combination of symptoms and a positive stool test result for C. 
difficile toxins or toxigenic C. difficile. Toxigenic culture is consid-
ered to be the reference method for the diagnosis of CDI, but is 
labor-intensive and time-consuming, which has limited its use in 
clinical laboratories [5]. Enzyme immunoassays (EIA) rapidly de-
tect toxins A and B, but their sensitivity varies greatly according 
to the assay kits [2, 3, 6]. Glutamate dehydrogenase (GDH), a 
common antigen of the C. difficile cell wall, is a sensitive marker 
for the detection of C. difficile, approaching 100% sensitivity [2, 
6, 7]. The GDH test detects non-toxigenic and toxigenic C. diffi-
cile as well as certain other clostridial species; therefore, it must 
be used in combination with a C. difficile toxin-detecting assay. 
It has been recommended that GDH be used as the first-line 
screening test, followed by the demonstration of toxigenic C. dif-
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ficile in GDH-positive stool specimens [2, 4, 8, 9]. In this study, 
we evaluated the C. DIFF QUIK CHEK COMPLETE (CD COM-
PLETE; TechLab, Blacksburg, VA, USA) assay, which uses a 
combination of GDH antigen detection and toxin A and B detec-
tion, and compared it to the currently used VIDAS Clostridium 
difficile A & B (VIDAS CDAB; bioMérieux, Marcy l’Etoile, France) 
assay and toxigenic cultures for the diagnosis of CDI.
 A total of 608 loose stool specimens were collected from sus-
pected CDI patients in a tertiary care teaching hospital from Au-
gust to December 2012. The CD COMPLETE and VIDAS CDAB 
assays were performed on the same day as specimen reception 
according to the manufacturer’s instructions. In brief, for the CD 
COMPLETE assay, 25 µL or an equivalent volume of stool speci-
men was added to a tube containing the diluent and conjugate 
(TechLab), and the mixture was transferred to the device sam-
ple well. After incubation for 15 min at room temperature, wash 
buffer and then substrate (TechLab) were added to the reaction 
window. Results were read after 10 min. GDH antigen and/or 
toxins were reported as positive, if a visible band was seen on 
the device display window (GDH+/tox+; GDH+/tox-; GDH-/tox-). 
Discrepancies in results between GDH and toxin A/B (AB) were 
resolved by using the toxigenic culture as a reference.
 In toxigenic culture, alcohol-shocked stool specimens were 
inoculated on C. difficile selective agar (CDSA; Becton, Dickin-
son and Company, Sparks, MD, USA) and incubated at 37°C in 
an anaerobic chamber (Forma Scientific, Marietta, OH, USA) for 
48 hr. The species were identified by using Gram staining and 
the ATB 32A system (bioMérieux). The identified C. difficile iso-
lates were used to detect toxin genes by PCR as described pre-
viously [10, 11]. C. difficile VPI 10463 (A+B+), 3608/03 (A−B−), 
and 1470 (A−B+) were used as controls for the PCR assays. PCR 
ribotyping of the C. difficile isolates was performed according to 
a previously described method with minor modifications [12].
 Stool specimens that were culture-negative and CD COM-
PLETE- or VIDAS CDAB-positive were analyzed by using an en-
richment procedure in pre-reduced taurocholate and cycloser-
ine-cefoxitin brain heart infusion broth (TCC broth), which was 
incubated for 48 hr at 37°C in an anaerobic atmosphere as pre-
viously described [13]. Each TCC broth was plated onto TCC 
agar. The McNemar test and chi square test were used for sta-
tistical analyses. This study was approved by the Yonsei Univer-
sity Health System (YUHS) Institutional Review Board (IRB #4-
2012-0231).
 C. difficile was isolated in 100 of 608 stool specimens 
(16.4%) by direct and enriched cultures. In direct culture, 62 C. 
difficile isolates (10.2%) were recovered and 55 (88.7%) iso-
lates were toxigenic. Discordant results were seen in 89 stool 
specimens (culture-negative and CD COMPLETE- or VIDAS 
CDAB-positive). Among them, 80 specimens were inoculated in 
selective enriched broth because of insufficient sample volume, 
with 38 (47.5%) of the specimens giving a positive C. difficile 
result, and 26 (68.4%) isolates were toxigenic.
 In comparison to the direct toxigenic cultures, sensitivity, spec-
ificity, positive predictive value (PPV), and negative predictive 
value (NPV) for the CD COMPLETE-toxin assay were 63.6%, 
98.0%, 76.1%, and 96.4%, respectively, and 75.5%, 97.4%, 
72.5%, and 97.8%, respectively, for the VIDAS CDAB assay 
(Table 1). Sensitivities and NPV were significantly different (P = 
0.025 and P =0.028, respectively).
 In comparison to the enriched C. difficile cultures, sensitivity, 
specificity, PPV, and NPV for the CD COMPLETE-GDH assay 
were 91.0%, 92.4%, 70.5%, and 98.1%, respectively (Table 2). 
The sensitivity, specificity, PPV, and NPV for the CD COMPLETE 
(GDH+toxin) assay were 93.0%, 92.2%, 70.5%, and 98.5%, 
respectively. CD COMPLETE-GDH assay showed significantly 
higher sensitivity, specificity, PPV, and NPV than the VIDAS 
CDAB assay (P <0.001).
 There were 81 (69 A+B+, 12 A−B+) isolates and 22 different ri-
botype patterns identified by PCR ribotyping. PCR ribotypes 018, 
017, and 014/020 were frequent and accounted for 25.9%, 
Table 1. Performance of C. DIFF QUIK CHEK COMPLETE-toxin AB and VIDAS Clostridium difficile A & B compared to toxigenic culture
Tests N of samples Results
Toxigenic culture (N) Sensitivity Specificity PPV NPV
Positive Negative % (95% CI)
CD COMPLETE- toxin 608 Positive 35 11 63.6 (50.9-76.3) 98.0 (96.8-99.2) 76.1 (63.8-88.4) 96.4 (94.9-97.9)
Negative 20 542
VIDAS 590* Positive 37 14 75.5 (63.5-87.5) 97.4 (96.1-98.7) 72.5 (60.2-84.8) 97.8 (96.6-99.0)
Negative 12 527
*Thirteen equivalent results and 5 samples not analyzed were excluded. 
Abbreviations: CD COMPLETE-toxin, C. DIFF QUIK CHEK COMPLETE-toxinAB; VIDAS, VIDAS Clostridium difficile A & B; PPV, positive predictive value; NPV, 
negative predictive value; CI, confidence interval.
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14.8%, and 13.6%, respectively, of the total. The detection rates 
of PCR ribotypes 018, 017, and 014/020 were 66.7%, 25.0%, 
and 36.4%, respectively, for the CD COMPLETE-toxin assay and 
76.2%, 25.0%, and 36.4%, respectively, for the VIDAS CDAB 
assay (Table 3).
 Among the 80 stool specimens in this study that were grown 
in enrichment culture because of discordant results, 73 were CD 
COMPLETE-GDH-positive and culture-negative. Among them, 
38 (47.5%) specimens were positive for C. difficile, and 26 iso-
lates (26/38, 68.4%) were toxigenic, with 14 different identified 
ribotype patterns including ribotype 017 (N=7), 018 (N=4), 
014/020 (N=2), and others (N=13). The majority (58.3%) of 
the specimens isolated in the enrichment procedure were ribo-
type 017.
 Similarly, in a recent study evaluating real-time PCR using the 
toxigenic culture as a reference method, toxigenic culture-nega-
tive and real-time PCR-positive specimens turned out to be pos-
itive for toxigenic C. difficile by the enriched culture process [13, 
14]. The use of enrichment broth was more sensitive than direct 
plating to agar, but was too time-consuming for routine diagnos-
tic cultures [15]. Therefore, enrichment cultures or additional 
real-time PCR tests are recommended for GDH-positive, culture-
negative samples. 
 The GDH test is recommended as an initial screening test be-
cause of its very high sensitivity [2, 4, 7, 9, 16], reported to be 
79.5-100%, and NPV, reported to be 94.6-100% [17]. The GDH 
test has high sensitivity and NPV, and thus would be a powerful 
test in a dual testing algorithm when combined with a test to de-
tect toxin. It was reported that specimens that were negative for 
GDH were not tested further because of the reported high NPV 
of the assay [16-18]. Our laboratory has performed VIDAS CDAB 
assays and toxigenic cultures for the diagnosis of CDI. We simu-
lated the two-step testing algorithm by applying the VIDAS CDAB 
and CD COMPLETE assays, followed by enriched toxigenic cul-
ture (Fig. 1). If CD COMPLETE assay had been used as an initial 
screening test with no further tests in 461 of 608 (75.8%) cases 
of GDH (-)/AB (-), 8 of 608 (1.3%) would have been false nega-
tives. When the GDH test had not been routinely used, 26 of 608 
(4.3%) would have been false negatives in this study. Therefore, 
the use of an initial screening with the CD COMPLETE assay in-
stead of the VIDAS CDAB assay has diagnostic and economic 
advantages in our laboratory.
 The toxin EIA test is not suitable as a stand-alone test for the 
diagnosis of CDI because of its low sensitivity and PPV, although 
it is the most common diagnostic laboratory method [2, 3, 6]. 
The performance of CD COMPLETE-toxin was comparable with 
VIDAS CDAB in this study.
 Recently, Tenover et al. [19] found that the sensitivities of 
EIAs, GDH, and Xpert C. difficile assays may vary according to 
ribotype. However, Goldenberg et al. [20] reported that there 
were no differences in the detection of GDH and PCR according 
to specific ribotypes. In this study, the isolation rate in enrich-
ment culture and the detection rates of VIDAS tended to vary ac-
cording to ribotype (P <0.05). The detection rates of CD COM-
PLETE-GDH, -toxin, and VIDAS were higher in ribotype 018, 
which was the most prevalent ribotype, than in other ribotypes. 
Both our study and that by Tenover et al. [19] used stool sam-
ples, while Goldenberg et al. [20] used cultured isolates. Gold-
enberg et al. [20] also suggested that this conflicting result could 
be explained by natural variations in the amount of organisms in 
Table 2. Performance of C. DIFF QUIK CHEK COMPLETE-GDH compared with enriched toxigenic culture
Test N of samples Results
Toxigenic culture (N) Sensitivity Specificity PPV NPV
Positive Negative % (95% CI)
GDH 599* Positive 91 38 91.0 (85.4-96.6) 92.4 (90.1-94.7) 70.5 (62.6-78.4) 98.1 (96.9-99.3)
Negative 9 461
*Nine samples insufficient for enrichment culture were excluded.
Abbreviations: GDH, C. DIFF QUIK CHEK COMPLETE-GDH; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval.
Table 3. Characteristics of prevalent toxigenic Clostridium difficile ribotypes
Rate (%) 018 (N=21) 017 (N=12) 014/020 (N=11) Other (N=37) Total (N=81) P
Isolation rate in enrichment culture 19.0 58.3 9.1 37.8 32.1 0.034
Detection rate of GDH 95.2 83.3 81.8 78.4 84.0 0.410
Detection rate of toxin 66.7 25.0 36.4 37.8 43.2 0.073
Detection rate of VIDAS 76.2 25.0 36.4 40.5 46.9 0.014
Abbreviations: GDH, C. DIFF QUIK CHEK COMPLETE-GDH; toxin, C. DIFF QUIK CHEK COMPLETE-toxin AB; VIDAS, VIDAS Clostridium difficile A & B.
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the stool samples tested.
 In conclusion, in comparison to both the direct and enriched 
culture specimens, the CD COMPLETE assay is a reliable method 
for the diagnosis of CDI, and provides greater sensitivity than the 
toxin EIA alone. Furthermore, the CD COMPLETE-GDH assay 
has advantages over direct culture in the detection of C. difficile.
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